论文部分内容阅读
目的 评价在急性脑梗死 (ACI)病后 6h尿激酶 (UK)静脉溶栓的临床疗效。方法 76例ACI随机分成两组 ,UK组和对照组。UK组UK2 5万单位静脉推注 ,续以UK15 0万U 60min内静滴 ,对照组采用通常的治疗方案 ,评价治疗前和治疗后 2 4h、1周、2周、4周的神经功能缺损评分。结果 ( 1)治疗后 2 4h、2周、4周时UK组与对照组比较改善均非常显著 (P <0 0 1) ;1周时UK组改善比较显著 (P <0 0 5 )。 ( 2 )UK组用药前与用药后 2 4h比较、1周与 2周比较、2周与 4周比较 ,神经功能缺损评分改善均非常显著 (P <0 0 1) ,用药后 2 4h与 1周比较 ,差异显著 ( P <0 0 5 )。 ( 3 )UK组用药后 2 4h时显效率 2 4 3 % ,1周时 5 7 1% ,2周时 81 3 % ,4周时 90 6% ,均高于同期对照组结果 (P <0 0 1,<0 0 1,<0 0 1,<0 0 5 )。结论 早期ACIUK溶栓治疗比常规治疗起效快、作用强、效果好 ,并且安全、简便和可靠
Objective To evaluate the clinical efficacy of intravenous thrombolysis with urokinase (UK) at 6 hours after acute cerebral infarction (ACI). Methods 76 cases of ACI were randomly divided into two groups, UK group and control group. UK group UK250000 unit intravenous bolus, followed by UK1500U U intravenous infusion within 60min, the control group using the usual treatment programs, evaluation of pre-treatment and after treatment 24h, 1 week, 2 weeks, 4 weeks of neurological deficits score. Results (1) The improvement of UK group and control group at 24 hours, 2 weeks and 4 weeks after treatment were all significantly improved (P <0.01); UK improved significantly at 1 week (P <0.05). (2) The scores of neurological deficits in UK group were significantly improved (P <0.01), compared with those at 24 hours after treatment, compared with those of 1 week and 2 weeks, and those of 2 weeks and 4 weeks after treatment Week, the difference was significant (P <0 05). (3) In the UK group, the effective rate was 24.3% at 24 hours, 57.1% at the first week, 81.3% at the second week and 90.6% at the fourth week, which were all higher than those in the control group at the same period (P <0 0 1, <0 0 1, <0 0 1, <0 0 5). Conclusion Early ACIUK thrombolytic therapy has faster onset, stronger effect and better effect than routine treatment, and is safe, simple and reliable